Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. MPLT
MPLT logo

MPLT

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

MPLT News

MapLight Therapeutics Executive Sells Shares

6d agoFool

MapLight Completes Enrollment in Schizophrenia Trial

May 01 2026NASDAQ.COM

Analysis of MapLight Therapeutics' Cash Burn

Apr 26 2026Yahoo Finance

MapLight Therapeutics Executive Sells Shares Amid Routine Liquidity Management

Apr 22 2026Fool

Biotech Stocks Reach New 52-Week Highs

Apr 09 2026NASDAQ.COM

MapLight Reports 2025 Financial Results and Clinical Milestones

Mar 26 2026NASDAQ.COM

MapLight Therapeutics Reports Q4 Financial Results

Mar 26 2026seekingalpha

Maplight Therapeutics Inc. Reports Q4 Net Loss of $79.5 Million, Q4 EPS at -$2.47

Mar 26 2026moomoo

Maplight and CVRx Executives Increase Stock Holdings

Feb 23 2026NASDAQ.COM

Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly

Jan 09 2026renaissancecapital

MapLight Accelerates Phase 2 Trial Timelines for Schizophrenia and Autism Studies

Jan 09 2026Globenewswire

MapLight Therapeutics Receives FDA Fast Track Designation for ML-007C-MA in Alzheimer's Treatment

Jan 05 2026NASDAQ.COM

MapLight Receives FDA Fast Track Designation for ML-007C-MA in Alzheimer's Disease Psychosis

Jan 05 2026Globenewswire

MapLight Receives FDA Fast Track Designation for ML-007C-MA in Alzheimer's Disease Psychosis

Jan 05 2026Newsfilter

Aktis Oncology Files for IPO in the U.S. Targeting $346 Million in Funding

Dec 19 2025Newsfilter

MapLight Therapeutics and SandboxAQ Partner to Create Treatments for Central Nervous System Disorders

Dec 16 2025Yahoo Finance